# MediSpan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medispan

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.medispan.co.kr
- Total disclosed funding: $5.8M
- Latest round: Series A (May 13, 2021)
- Investors on record: 3

## About

Founded in 2020 and based in Seongnam, South Korea, MediSpan operates as a biotechnology company that develops immunotherapies for anti-aging. In May 2021, MediSpan raised KRW 6.5 billion in Series A funding from new investors DSC Investment, Starset Investment, and Tigris Investment. As of May 2023, the company is being led by its Founder and CEO, KyungA Cho.



The company creates medications and therapies for age-related illnesses like inflammatory growth disorders, nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and infectious diseases. The business offers immunotherapies that support aging improvement and the treatment of geriatric diseases using its patented processes, allowing patients to experience improved aging and healthy life extension.

## Funding rounds

- Series A, May 13, 2021, $5.8M — DSC Investment, Tigris Investment, Starset Investment

## Investors

- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- Tigris Investment (https://capitalatlas.ai/funds/tigris-investment) — Series A
- Starset Investment — Series A